Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1995 Sep;121(9-10):587–592. doi: 10.1007/BF01197775

Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: Comparison of adenovirus- and retrovirus-mediated genetic transduction

Junko Abe 1, Hiroaki Wakimoto 1,2, Yoko Yoshida 1, Masaru Aoyagi 2, Kimiyoshi Hirakawa 2, Hirofumi Hamada 1,✉
PMCID: PMC12200113  PMID: 7559742

Abstract

Irradiated tumor cells genetically modified to secrete granulocyte/macrophage-colony-stimulating factor (GM-CSF tumor vaccine) are potent stimulators of systemic antitumor immunity. For the preparation of a GM-CSF gene-modified tumor vaccine, it is important to achieve efficient genetic transduction of tumor cells, leading to an appropriate expression of the induced gene. In this report, with a view to developing a protocol for an effective cancer vaccination therapy, we examined the vaccination efficacies of tumor cells secreting GM-CSF by either adenovirus-or retrovirus-mediated genetic transduction. By using an adenoviral vector, Adex1CAmGMCSF, a highly efficient gene were achieved. Unexpectedly, animal vaccination studies showe that the GM-CSF tumor vaccine transduced with the Adex1CAmGMCSF recombinant adenovirus (adenoviral GM-CSF tumor vaccine) was less efficacious than that transduced with the MFGmGMCSF recombinant retrovirus (retroviral GM-CSF tumor vaccine). The GM-CSF serum concentration attained by the adenoviral GM-CSF tumor vaccine was much higher than that obtained by the retroviral GM-CSF tumor vaccine. Our findings indicate that an optimal level of GM-CSF production is important for the tumor vaccine to elicit an adequate response in the host antitumor immunity.

Key words: Tumor vaccine, GM-CSF, Adenoviral vector

Abbreviations

GM-CSF

granulocyte/macrophage-colony-stimulating factor

IL-2

interleukin-2

TNF

tumor necrosis factor

References

  1. Abe J, Wakimoto H, Nakamura Y, Kanegae Y, Saito I, Aoyagi M, Hirakawa K, Hamada H (1994) Immunogene therapy for cancer by cytokine gene-modified tumor vaccine and tumor-infiltrating lymphocytes (TIL). Cancer Gene Ther 1:312 [Google Scholar]
  2. Abe J, Wakimoto H, Nakamura Y, Aoyagi M, Hirakawa K, Hamada H (1995) Cytokine gene-modified tumor vaccination intensified by a streptococcal preparation OK432. Cancer Immunol Immunother (in press) [DOI] [PMC free article] [PubMed]
  3. Anderson WF (1994) Gene therapy for cancer. Hum Gene Ther 5:1–2 [DOI] [PubMed] [Google Scholar]
  4. Aoki T, Tashiro K, Miyatake S, Kinashi T, Nakano T, Oda Y, Kikuchi H, Honjo T. (1992) Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA 89:3850–3854 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Asher AL, Mulé JJ, Kasid A, Restifo NP, Solo JC, Reichert CM, Jaffe G, Fendly B, Kriegler M, Rosenberg SA (1991) Murine tumor cells transduced with the gene for tumor necrosis factor-α. J Immunol 146:3227–3234 [PMC free article] [PubMed] [Google Scholar]
  6. Attia MAM, Weiss DW (1966) Immunology of spontaneous mammary carcinomas in mice V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res 26:1787–1800 [PubMed] [Google Scholar]
  7. Chen Lk Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093–1102 [DOI] [PubMed] [Google Scholar]
  8. Colombo MP, Forni G (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15:48–51 [DOI] [PubMed] [Google Scholar]
  9. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E (1993) Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 177:1127–1134 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Danos O, Mulligan, RC (1988) Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 85:6460–6464 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539–3543 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397–403 [DOI] [PubMed] [Google Scholar]
  13. Fidler IJ (1975) Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 35:218–224 [PubMed] [Google Scholar]
  14. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990a) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217–1224 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E (1990b) Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50:7820–7825 [PubMed] [Google Scholar]
  16. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713–716 [DOI] [PubMed] [Google Scholar]
  17. Hanada K, Wakimoto H, Abe J, Orimoto K, Nakamura Y, Murata M, Hayashi M, Hamada H (1994) Strategies for immunogene therapy against cancer. Proc Nagoya Int Symp Cancer Chemother 9:73–80 [Google Scholar]
  18. Hamada H (1994)_Tumor vaccines expressing cytokine genes: combination with adoptive immunogene therapy for cancer. Proc Hiroshima Cancer Semin 4:17–20 [Google Scholar]
  19. Nakamura Y, Wakimoto H, Abe J, Kanagae Y, Saito I, Aoyagi M, Hirakawa K, Hamada H (1994) Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin-2. Cancer Res 54:5757–5760 [PubMed] [Google Scholar]
  20. Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193–200 [DOI] [PubMed] [Google Scholar]
  21. Pardoll DM (1993) Cancer vaccines. Immunol Today 14:310–316 [DOI] [PubMed] [Google Scholar]
  22. Porgador A, Tzehoval E, Katz A, Vadai E, Revel M, Feldman M, Eisenbach L (1992) Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 52:3679–3686 [PubMed] [Google Scholar]
  23. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L (1993) Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells. J Immunol 150:1458–1470 [PubMed] [Google Scholar]
  24. Saito I, Oya Y, Yamamoto K, Yuasa T, Shimojo H (1985) Construction of nondefective adenovirus type 5 bearing a 2.8-kilobase hepatitis B virus DNA near the right end of its genome. J Virol 54:711–719 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Saito S, Bannerji R, Gansbacher B, Rosenthal FM, Romanenko P, Heston WDW, Fair WR, Gilboa E (1994) Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 54:3516–3520 [PubMed] [Google Scholar]
  26. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC, Simons JW (1994) Dernonstration of a rational strategy for human prostate cancer gene therapy. J Urol 151:622–628 [DOI] [PubMed] [Google Scholar]
  27. Schmidt W, Schweighoffer T, Herbst E, Berger M, Schilcher F, Schaffner G, Birnstiel M (1995) Cancer vaccines: The interleukin 2 dosage effect. Proc Natl Acad Sci USA 92:4711–4714 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Tepper RI, Mulé JJ (1994) Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 5:153–164 [DOI] [PubMed] [Google Scholar]
  29. Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503–512 [DOI] [PubMed] [Google Scholar]
  30. Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368–370 [DOI] [PubMed] [Google Scholar]
  31. Vieweg J, Rosenthal FM, Bannerji R, Heston WDW, Fair WR, Gansbacher B, Gilboa E (1994) Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54:1760–1765 [PubMed] [Google Scholar]
  32. Wakimoto H, Abe J, Nakamura Y, Kanegae Y, Saito I, Aoyagi M, Hirakawa K, Hamada H (1994) Enhanced antitumor effects by vaccines and IL-2-secreting cytotoxic T lymphocytes. Gene Therapy, Cold Spring Harbor Laboratory, Cold Spring Harbor NY, p 164 [Google Scholar]
  33. Yamaguchi S, Wakimoto H, Yoshida H (1995) Enhancement of retrovirus-mediated gene transduction efficiency by transient overexpression of the amphotropic receptor, GLVR2. Nucleic Acids Res 23:2080–2081 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Yang G, Hellström KE, Hellström I, Chen L (1995) Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 154:2794–2800 [PubMed] [Google Scholar]
  35. Zatloukal K, Schneeberger A, Berger M, Schmidt W, Koszik F, Kutil R, Cotten M, Wagner E, Buschle M, Maass G, Payer E, Stingl G, Birnstiel ML (1995) Elicitation of a systemic and protective antimelanoma immune response by an IL-2-based vaccine. J Immunol 154:3406–3419 [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES